Camp del Corazon and others are made for children with complex health conditions, writes columnist Jolie Lizana.

Cereno will partner with PHA Europe & Global on patient-centered drug design for pulmonary hypertension medications.

Living with PH and transplant often involves a lack of privacy, but columnist Anna Jeter has found ways to preserve her ...

Tectonic sees top-line results from a Phase 2 trial of TX45 in PH with heart failure with preserved ejection fraction by ...

Mannkind and United Therapeutics are creating an inhaled formulation of ralinepag, an experimental oral PAH treatment.

Treatment with treprostinil led to significant and sustained improvements in children with PH associated with lung disease, ...

The analysis revealed dozens of genes with abnormal expression in cells from people with idiopathic PAH, and the researchers ...

“This study provides comprehensive preclinical evidence that the novel PDE5 inhibitor CPD1 is a potent therapeutic candidate ...

Pulmonary hypertension (PH) is caused by high blood pressure in the lungs, which is caused by narrowed and thickened pulmonary arteries. Because of the added effort needed to pump blood through the ...

Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical role of clinical research. Led by PHA Europe, the annual event seeks to raise ...

Corvista Health and Mayo Clinic will study whether Corvista-PH can improve pulmonary hypertension diagnosis and referrals.